Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT06303505 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC(NAPISTAR1-01) | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 8 | Sep 14, 2026 |
| clinicaltrials |
| NCT06674811 | Biomarkers of Resiliency In Childhood Cancer Surgery(BRICCS) | recruiting | — | 40 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06787612 | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | recruiting | Phase 2 | 297 | Regeneron PharmaceuticalsINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT07098182 | Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique) | recruiting | N/A | 50 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07539844 | Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries(ConFeR) | recruiting | — | 1,000 | AbbVieINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT07772869 | Uterine Lavage to Detect Ovarian Cancer Risk | recruiting | N/A | 75 | University of WashingtonOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04633239 | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05123482 | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | recruiting | Phase 1 / Phase 2 | 460 | AstraZenecaINDUSTRY | 15 | Sep 11, 2026 | clinicaltrials |
| NCT05979493 | QL Block in Laparoscopic Myomectomy | recruiting | Phase 4 | 80 | Joseph Findley MDOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06840002 | A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 150 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06964009 | DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer | recruiting | Phase 1 | 30 | Elizabeth Stover, MD, PhDOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07065552 | Tirzepatide in Obesity-Driven Endometrial Cancer | recruiting | Early Phase 1 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07546578 | Setting Up ctDNA Analysis on Archived Plasma Samples(DARE-part1) | recruiting | — | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07816263 | Guaraná Supplementation for Cancer-Related Fatigue(GUARANA-CRF) | recruiting | — | 60 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04865887 | Pembrolizumab and Lenvatinib in Advanced Cervical Cancer | recruiting | Phase 2 | 35 | Georgetown UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06293898 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | recruiting | Phase 1 | 280 | SystImmune Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06646627 | Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors | recruiting | Phase 1 | 48 | Stanford UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07502157 | Massage, Oncology, Pain, Anxiety, Feasibility(IMPACT) | recruiting | N/A | 24 | Jill ColeOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03651206 | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib(ROCSAN) | recruiting | Phase 2 / Phase 3 | 138 | ARCAGY/ GINECO GROUPOTHER | 3 | Sep 9, 2026 | clinicaltrials |
| NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer(RAINFOL-03) | recruiting | Phase 3 | 660 | GenmabINDUSTRY | 19 | Sep 9, 2026 | clinicaltrials |
| NCT07604766 | An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China(RAINFOL-02) | recruiting | Phase 3 | 82 | GenmabINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07676890 | A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery(NeoOVIV) | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07724106 | A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery(NeoOVSV) | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04585958 | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer | recruiting | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07041606 | An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation(IREN) | recruiting | — | 500 | AstraZenecaINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07808164 | ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort | recruiting | — | 162 | Tam Anh Research InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06430541 | Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence | recruiting | Phase 1 | 20 | University of Colorado, DenverOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors(NEXUS-01) | recruiting | Phase 1 | 420 | Eli Lilly and CompanyINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT07613723 | A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies | recruiting | Phase 1 | 9 | Zelluna Immunotherapy ASINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT01617382 | Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed(HIPEC) | recruiting | — | 125 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05950464 | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | recruiting | Phase 1 | 65 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06515613 | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 156 | Context Therapeutics Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06989112 | DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer(DE-01) | recruiting | Phase 3 | 600 | AstraZenecaINDUSTRY | 23 | Sep 3, 2026 | clinicaltrials |
| NCT07194551 | Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire(Lynch-SCAN) | recruiting | N/A | 30 | University of British ColumbiaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07755436 | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. | recruiting | Phase 1 | 180 | ArriVent BioPharma, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04188535 | Serial MRI Scans During Radiation Therapy(RELAY) | recruiting | N/A | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | recruiting | — | 2,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06904365 | Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women(OvAR-Y) | recruiting | — | 11 | Washington University School of MedicineOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06995833 | Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance | recruiting | — | 50 | AstraZenecaINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06995898 | The Vanguard Study: Testing a New Way to Screen for Cancer | recruiting | N/A | 24,000 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07216105 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 119 | Fate TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07796672 | Feasibility Study of Blood Biomarker Identification in Cervical Cancer(CLARITY) | recruiting | — | 100 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07736937 | Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer(OC) | recruiting | Phase 1 / Phase 2 | 72 | Tubulis GmbHINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT04839614 | Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials